Developing less risky products New products, safer choices? To help people understand the relative risks of different types of tobacco and nicotine products, they can be placed on a risk continuum model based on exposure to toxicants. HIGH EXPOSURE LOW EXPOSURE Conventional Cigarettes Tobacco Heating Products Low‑toxicant Smokeless Tobacco Vapour Products (e‑cigarettes) Licensed Medicinal Products We are committed to researching, developing and commercialising less risky alternatives to regular cigarettes. For society, less risky alternatives have the potential to reduce smoking-related disease, while also being an area of commercial growth for our business. We have invested significant time, funds and resources into developing high-quality Next Generation Products. We are focused on three distinct product categories and have made considerable progress in building our range and expanding into new markets. Vapour Products (e-cigarettes) Our Vype brand was first launched in the UK in 2013. Since then we have used our experience and consumer insights to develop the range, adding new flavours and devices, such as the eTank, a refillable device. In 2015, we launched Vype in five further markets – Italy, France, Poland, Germany and Colombia. Licensed Medicinal Products We became the first tobacco company to have a nicotine product licensed as a medicine, following receipt of the relevant licences from the UK medicines regulator for our innovative nicotine inhaler, Voke. We plan to launch Voke in the UK later in 2016. Tobacco Heating Products In 2015, we launched our first Tobacco Heating Product, glo iFuse, in Romania. This is an electronic device that heats a nicotine containing liquid into an inhalable vapour, which then passes through a tobacco section, releasing tobacco flavour to the consumer. We also continue to work on other types of innovative Tobacco Heating Products, with plans to test market a new product in 2016. Capabilities, commitment, ambition Next Generation Products Using science to increase our understanding Research and Development External links bat-science.com Our products About tobacco Cigarettes Cigars E-cigarettes and other Next Generation Products Snus The health risks of our products Harm reduction The independent evidence Developing less risky products R&D virtual tour Search BATS: LSE GBp 4698.00 (+2.50) About us Sustainable business Our industry Challenges and opportunities How we work From crop to consumer Our products Putting consumers first Next Generation Products Capabilities, commitment, ambition Sustainability Investors Media Reporting Careers Contact us Worldwide Home Our products Harm reduction Developing less risky products Explore our world We are one of the world’s most international businesses and many of our Group companies have their own websites. @BATPress BAT Press Office @BATPress 'Warning: junk science damages your health'. Interesting piece on #vaping from @mattwridley in @thetimes (paywall) ow.ly/9mH53047Cpg 12 Sep Reply Retweet Favorite BAT Press Office @BATPress Watch: @OliverWParry of @The_IoD talks to @IanKingSky about our #CorpGov #1 ranking executiveinterviews.com/delivery/v1/so… 09 Sep Reply Retweet Favorite Investors Current UK share price 4698.00p +2.50p 13/09/2016 05:12 Our reporting Contact us +44 (0) 20 7845 1000 British American Tobacco p.l.c. Globe House 4 Temple Place London WC2R 2PG © British American Tobacco Accessibility Conditions of use Financial information Privacy policy Cookie policy Site map